Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis of tumor cells but not most normal cells. Its roles in normal nontransformed tissues are not clear.

NT-Apo2L/TRAIL did not trigger more than 5% of the ... Apoptosis induced in normal human hepatocytes by tumor necrosis factor- related apoptosis-inducing ligand. Nature Med. 6, 564–567 (2000).

TNF Pharmaceuticals (TNFA) announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha inhibitor drug ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) with focused ultrasound (FUS) can significantly reduce tumor size and ...

As well as a chimeric antigen receptor (CAR), ONK adds a tumor necrosis factor (TNF)–related apoptosis ligand (TRAIL) variant to create dual-targeted CAR-NK cells (Fig. 1).

BALTIMORE, February 25, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed ...

TNF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, has announced the initiation of a fully funded ...

The CD95 and tumor necrosis factor (TNF) ligand/receptor systems play an essential role in various apoptotic mechanisms. To determine the involvement of these ligands in SCI-induced damage ...